Table 5.
Subgroup analysis of overall survival in the phase III studies of eribulin by human epidermal growth factor receptor 2 (HER2) and oestrogen receptor (ER) status
| 305 (EMBRACE) [30] | 301 [31, 32] | |||||
|---|---|---|---|---|---|---|
| OS (months) | HR (95 % CI) | OS (months) | HR (95 % CI) | |||
| Eribulin | TPC | Eribulin | CAP | |||
| Total | 13.2 | 10.5 | 0.81 (0.66, 0.99) | 15.9 | 14.5 | 0.88 (0.77, 1.00) |
| HER2+ | 11.3 | 9.1 | 0.76 (0.47, 1.24) | 14.3 | 17.1 | 0.97 (0.69, 1.36) |
| HER2− | 13.2 | 10.5 | 0.81 (0.64, 1.02) | 15.9 | 13.5 | 0.84 (0.72, 0.98) |
| ER+ | 13.8 | 11.4 | 0.81 (0.63, 1.04) | 18.2 | 16.8 | 0.90 (0.74, 1.09) |
| ER− | 10.2 | 7.8 | 0.78 (0.54, 1.13) | 14.4 | 10.5 | 0.78 (0.64, 0.96) |
| TN | 9.5 | 7.0 | 0.71 (0.46, 1.10) | 14.4 | 9.4 | 0.70 (0.55, 0.91) |
CAP capecitabine, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, TN triple negative, TPC treatment of physician’s choice